What is NDC 16714-891?

16714-891 is the product NDC for Sumatriptan and Naproxen Sodium, Sumatriptan succinate 85 mg/1; Naproxen sodium 500 mg/1 tablet, film coated, listed with the FDA by NorthStar RxLLC. It has 1 package NDC, shown above in 10- and 11-digit form.

What is the active ingredient?

Sumatriptan succinate, Naproxen sodium.

NorthStar RxLLC, NDC labeler code 16714. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Sumatriptan and Naproxen Sodium?

2 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Sumatriptan and Naproxen Sodium NDC 16714-891

NDC codes

FDA NDC Directory

Product NDC (as listed)16714-891Labeler and product segments. Claims need a package NDC.

Product NDC at billing width16714-0891Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
16714-891-01	1671408910116714089101	9 TABLET, FILM COATED in 1 BOTTLE (16714-891-01)Marketed from Nov 27, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sumatriptan and Naproxen Sodium
Generic name (nonproprietary): sumatriptan and naproxen sodium
Active ingredients: Sumatriptan succinate — 85 mg/1Naproxen sodium — 500 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: NorthStar RxLLCNDC labeler code 16714
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202803
Marketing start: Nov 27, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Non-Steroidal (Chemical structure)Cyclooxygenase Inhibitors (Mechanism)Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
Identifiers: Product ID 16714-891_c5920565-605b-45cb-8da9-4d418ec3b356SPL ID c5920565-605b-45cb-8da9-4d418ec3b356SPL set ID 3f2ec27e-0e96-4028-a1fa-114e6d501464RxCUI 849450UNII J8BDZ68989, 9TN87S3A3CUPC 0316714891019
Pharmacologic class: Nonsteroidal Anti-inflammatory Drug; Serotonin-1b and Serotonin-1d Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N416714089101 followed by a unit qualifier and the quantity

Package 16714-0891-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 20, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Sumatriptan and naproxen sodium tablets are indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan and naproxen sodium tablets, reconsider the diagnosis of migraine before sumatriptan and naproxen sodium tablets are administered to treat any subsequent attacks. Sumatriptan and naproxen sodium tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of sumatriptan and naproxen sodium tablets have not been established…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 16714-891

What is NDC 16714-891?: 16714-891 is the product NDC for Sumatriptan and Naproxen Sodium, Sumatriptan succinate 85 mg/1; Naproxen sodium 500 mg/1 tablet, film coated, listed with the FDA by NorthStar RxLLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Sumatriptan and Naproxen Sodium.
What is the active ingredient?: Sumatriptan succinate, Naproxen sodium.
Who is the labeler?: NorthStar RxLLC, NDC labeler code 16714. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Sumatriptan and Naproxen Sodium?: 2 other product NDCs are listed under this name. See all Sumatriptan and Naproxen Sodium NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Sumatriptan and Naproxen Sodium NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Sumatriptan and Naproxen Sodium	Sumatriptan succinate 85 mg/1; Naproxen sodium 500 mg/1	Tablet, Film coatedOral	Sun Pharmaceutical Industries, Inc.	47335-410	47335-0410-2247335-0410-8347335-0410-88
Sumatriptan and Naproxen Sodium	Sumatriptan succinate 85 mg/1; Naproxen sodium 500 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	65862-928	65862-0928-36

Other NDCs under ANDA 202803

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202803
Product	Strength	Form · route	Labeler	Product NDC
Sumatriptan and Naproxen Sodium	Sumatriptan succinate 85 mg/1; Naproxen sodium 500 mg/1	Tablet, Film coatedOral	Sun Pharmaceutical Industries, Inc.	47335-410